| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| mk-2206 | rac-gamma serine/threonine-protein kinase | NA | Clinical trial target | TTD , DGIDB | Rectum[MeSHID:D012007] Adenocarcinoma[MeSHID:D000230] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Nasopharyngeal carcinoma[MeSHID:C538339] |
0.98 | phase 2 | unknown |
| mk-2206 | rac-gamma serine/threonine-protein kinase | NA | Clinical trial target | TTD , DGIDB | Rectum[MeSHID:D012007] Adenocarcinoma[MeSHID:D000230] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Nasopharyngeal carcinoma[MeSHID:C538339] |
0.98 | phase 2 | allosteric modulator |
| mk-2206 | rac-gamma serine/threonine-protein kinase | NA | Clinical trial target | TTD , DGIDB | Rectum[MeSHID:D012007] Adenocarcinoma[MeSHID:D000230] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Nasopharyngeal carcinoma[MeSHID:C538339] |
0.98 | phase 2 | inhibitor |
| mk-2206 | e2 ubiquitin-conjugating enzyme t | NA | Clinical trial target | TTD , DGIDB | Rectum[MeSHID:D012007] Adenocarcinoma[MeSHID:D000230] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Nasopharyngeal carcinoma[MeSHID:C538339] |
3.74 | phase 2 | unknown |
| click here to return to the previous page | ||||||||